Viking Therapeutics Initiates Phase 1 Ascending Dose Trial Of VK3019, An Investigational Dual Amylin And Calcitonin Receptor Agonist For Weight Loss; Data Expected In 3Q26

뉴스 본문을 불러오고 있어요.

Viking Therapeutics Initiates Phase 1 Ascending Dose Trial Of VK3019, An Investigational Dual Amylin And Calcitonin Receptor Agonist For Weight Loss; Data Expected In 3Q26 | 웨이프 WAPE

Viking Therapeutics Initiates Phase 1 Ascending Dose Trial Of VK3019, An Investigational Dual Amylin And Calcitonin Receptor Agonist For Weight Loss; Data Expected In 3Q26

기사 요약

관련 종목

댓글 —